【ChiCTR2500111062】Maintenance Venetoclax Based Therapy Post Complete Remission In AML Fit Patients
ChiCTR2500111062
尚未开始
/
/
/
2025-10-24
/
/
acute myeloid leukemia
Maintenance Venetoclax Based Therapy Post Complete Remission In AML Fit Patients
Maintenance Venetoclax Based Therapy Post Complete Remission In AML Fit Patients
The aim of this study is to explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.
随机平行对照
Ⅲ期
The randomization sequence will be generated by an independent statistician using a computer-based random number generator. Patients will be allocated in a 1:1 ratio to receive Venetoclax maintenance or placebo
Investigators and participants will remain blinded to the treatment allocation, ensuring that neither the enrollment process nor subsequent assessments are biased.
Sohag university
/
40
/
2025-11-01
2027-10-10
/
1-Age : 18 - 60 years . 2-Patients who are not eligible for immediate bone marrow transplantation. 3-Newly diagnosed AML patients who attained CR after 1st line. 4-Refractory / recurrant AML patients .；
请登录查看1-Patients not on CR . 2-Age : younger than 18 or older than 60 3-Patients not eligible for bone marrow transplation；
请登录查看Sohag university
/
Sohag university的其他临床试验
- Evaluation of blood and nerve functions among household contacts of leprosy patients in Sohag governorate
- Maintenance Venetoclax Based Therapy Post Complete Remission In AML Fit Patients
- A Comparative study between Induction Chemotherapy Followed by Concurrent Chemoradiation versus Concurrent Chemoradiation in the Management of Locally Advanced Uterine Cervical Cancer
Sohag university的其他临床试验
- Evaluation of blood and nerve functions among household contacts of leprosy patients in Sohag governorate
- Maintenance Venetoclax Based Therapy Post Complete Remission In AML Fit Patients
- A Comparative study between Induction Chemotherapy Followed by Concurrent Chemoradiation versus Concurrent Chemoradiation in the Management of Locally Advanced Uterine Cervical Cancer
- THE OUTCOME OF MULTIDISCIPLINARY MANAGEMENT OF CAROTID BODY TUMORS: A RETROSPECTIVE COHORT STUDY
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04